Guggenheim analyst Chris Pasquale downgrades icad (NASDAQ:ICAD) from Buy to Neutral.
Guggenheim Downgrades icad to Neutral
Guggenheim analyst Chris Pasquale downgrades icad (NASDAQ:ICAD) from Buy to Neutral.
Related Posts
Credit Suisse Maintains Outperform on Farfetch, Lowers Price Target to $47
Credit Suisse analyst Stephen Ju maintains Farfetch (NYSE:FTCH) with a Outperform and lowers the price target from $55 to $47.
Donald Trump Nullifies 92% Of Joe Biden’s Autopen-Signed Documents: ‘Cancelling All Executive Orders And Anything Else’
Trump moved to invalidate what he claims are most of Biden's autopen-signed actions, sparking political backlash and renewed debate over the legality and precedent of using mechanical signatures for presidential documents.
AstraZeneca Announced CALQUENCE Plus Obinutuzumab Demonstrated Sustained Survival Benefit in 1st-line Chronic Lymphocytic Leukemia with 90% of Patients Surviving Five Years in ELEVATE-TN Trial in Data Presented at ASCO
Updated results from the ELEVATE-TN Phase III trial showed AstraZeneca's CALQUENCE®(acalabrutinib) maintained a statistically significant progression-free survival (PFS) benefit versus chlorambucil plus obinutuzumab and a safety and tolerability profile consistent with the known profile for CALQUENCE at a median follow up of approximately five years in combination and as a monotherapy in chronic l